Zydus Lifesciences arm to acquire U.S. oncology firm Assertio for $166 million
Under the terms of the merger agreement, Zydus will commence a tender offer to acquire all outstanding shares of Assertio common stock
Under the terms of the merger agreement, Zydus will commence a tender offer to acquire all outstanding shares of Assertio common stock
What's Your Reaction?
